TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Saturday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

NASDAQ TXMD opened at $1.52 on Friday. TherapeuticsMD has a fifty-two week low of $1.43 and a fifty-two week high of $3.07. The stock has a 50 day simple moving average of $1.64 and a two-hundred day simple moving average of $1.80.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The company had revenue of $0.23 million during the quarter.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the quarter. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.